On July 1st, the commissioning ceremony of Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. was held in Taizhou Bay Economic Development Zone. The event was attended by Xie Pingyi, member of the party's working committee and Executive Deputy Director of the management committee of Taizhou Bay Economic and Technological Development Zone, Jiuzhou Pharmaceutical Chairman Lirong Hua, President of Jiuzhou Pharmaceutical David Mei, well-known domestic innovative pharmaceutical companies such as Hutch-Med Pharmaceutical, Ascentage Pharmaceutical, and Betta Pharmaceutical, and about 300 employees of Jiuzhou Pharmaceutical to witness another important milestone in the development of Jiuzhou.

And during the ceremony, David Mei, President of Jiuzhou Pharmaceutical Company, expressed his deep gratitude to government entities and partners for their strong support and assistance and accentuated the full efforts made by Jiuzhou Pharmaceutical (Taizhou) employees to complete and operate this project. In his speech, David Mei indicated the importance of this milestone in Jiuzhou Pahrma's journey to realize its vision of becoming a Life and Health Excellence Enterprise and Global Drug Innovation Source, which will have an enormous impact on Jiuzhou's business development.

He also emphasized the company's commitment to its values, where the customer is Jiuzhou's first priority, product and service development is a continuous process, and Jiuzhou's business expansion is a must to serve a wider range of customers.

Dr. Wu Zhenping, Executive Vice President of Hutch-Med Pharmaceutical Co., LTD, extended his best wishes to the establishment of Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. and stressed that Jiuzhou Pharma is an old friend and a good partner pf Hutch-Med Pharma. Dr. Wu said that Jiuzhou Pharma has always been a high standard company that provides high quality products and efficient services, and thereby gained the trust of the market and the customers. In his speech Dr. Wu expressed his hopes that both sides will further extend and strengthen their cooperation to provide the patients in China and around the world with the best innovative drugs.

On Behalf of Taizhou Bay Economic and Technological Development Zone, Xie Pingyi, member of the party's working committee and Executive Deputy Director of the management committee, congratulated Jiuzhou Pharmaceutical (Taizhou) on its official commissioning. He pointed out that the project is considered an important step in Jiuzhou's CDMO business and  a consolidation of Jiuzhou's position in the industry. Xie Pingyi affirmed that Jiuzhou's new production project will upgrade the pharmaceutical industry in Taizhou Bay Economic and Technological Development Zone.

Subsequently, Hua Lirong, Chairman of Jiuzhou Pharmaceutical with the leaders and guests at the ceremony created a themed Calligraphy with golden sand that states: "Innovation and Development Empowers the Future", in an indication to the anticipation of Jiuzhou Pharmaceutical (Taizhou)'s success.

Forge ahead and set off steadily! The official commissioning of the new base of Jiuzhou Pharmaceutical (Taizhou) marks another important step in the industrial plan of Jiuzhou Pharmaceutical, which will surely provide better professional technical solutions and more reliable services for global pharmaceutical companies and contribute to the green and sustainable development of the pharmaceutical industry.

ABOUT Jiuzhou Pharmaceutical (Taizhou) Co. LTD.

Jiuzhou Pharmaceutical (Taizhou) Co., Ltd., founded in 2021 and located in Taizhou Bay Economic and Technological Development Zone, Zhejiang Province, focuses on R&D production of API and intermediates from preclinical and toxicology approval studies to commercial production according to GMP guidelines to create new drugs.

The project covers an area of about 300 acres, with a plan to construct a smart factory. The implementation is in three phases. The first phase of the project started in November 2021, with an annual production capacity of about 400 tons of innovative drug APIs and intermediates. After the completion of the project, it will further enhance the company's one-stop service capability for the integrated life cycle of drugs, from preclinical to commercialization, and empower more new drugs to accelerate the drug listing process.